Sep 8, 2026 08:02AM
Sep 8, 2026 08:00AM
Jan 12, 2026 09:10AM
Jan 12, 2026 09:10AM
Dec 30, 2025 09:20AM
Dec 30, 2025 09:20AM
Dec 23, 2025 09:29AM Lexaria achieves primary endpoint in Phase 1b GLP-1 study
Dec 23, 2025 09:29AM
Nov 12, 2025 09:11AM
Nov 12, 2025 09:10AM
Oct 9, 2025 09:20AM
Oct 9, 2025 09:20AM
Sep 29, 2025 04:30PM
Sep 29, 2025 04:30PM Lexaria Bioscience Corp. Announces Closing of $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Sep 19, 2025 11:25AM
Sep 19, 2025 11:20AM
Aug 27, 2025 09:20AM
Aug 14, 2025 09:20AM
Aug 14, 2025 09:20AM
Aug 6, 2025 09:20AM
Jul 28, 2025 09:25AM Lexaria reports reduced side effects in GLP-1 drug trial
Jul 28, 2025 09:25AM
Jul 23, 2025 09:28AM
Jul 23, 2025 09:25AM
Jun 23, 2025 09:15AM
Jun 23, 2025 09:15AM
Jun 11, 2025 09:05AM
Jun 11, 2025 09:05AM Lexaria's DehydraTECH-Liraglutide Human GLP-1 Clinical Study Supports Pathway to Potential FDA Registration as an Orally-Delivered Capsule
Jun 5, 2025 09:20AM
Apr 28, 2025 04:15PM
Apr 25, 2025 08:02AM
Apr 25, 2025 08:00AM
Apr 23, 2025 09:10AM
Apr 2, 2025 09:13AM
Apr 2, 2025 09:05AM Lexaria's Human GLP-1 Study #5 Begins Dosing
Mar 18, 2025 09:16AM
Mar 18, 2025 09:15AM
Feb 27, 2025 08:00AM
Feb 24, 2025 08:02AM
Feb 24, 2025 08:00AM
Feb 11, 2025 08:03AM
Feb 11, 2025 08:00AM Lexaria Granted Two New DehydraTECH Patents for Treatment of Epilepsy
Feb 6, 2025 09:42AM
Feb 6, 2025 09:40AM
Jan 30, 2025 09:17AM
Jan 30, 2025 09:15AM
Jan 15, 2025 09:28AM
Jan 15, 2025 09:20AM
Jan 14, 2025 09:12AM Lexaria Bioscience's (LEXX) Oral DehydraTECH-Tirzepatide Reduces Side Effects by Half with Comparable Efficacy Versus Eli Lilly's Injectable GLP-1/GIP Drug Zepbound
Dec 19, 2024 09:05AM

330,698 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All